Beam Therapeutics (NASDAQ:BEAM – Get Free Report) and Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.
Risk & Volatility
Beam Therapeutics has a beta of 2.2, indicating that its stock price is 120% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.
Valuation and Earnings
This table compares Beam Therapeutics and Celldex Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Beam Therapeutics | $139.74 million | 21.31 | -$79.99 million | ($0.86) | -33.52 |
| Celldex Therapeutics | $1.54 million | 1,510.94 | -$258.76 million | ($4.35) | -6.81 |
Beam Therapeutics has higher revenue and earnings than Celldex Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Beam Therapeutics and Celldex Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beam Therapeutics | -54.75% | -30.71% | -24.07% |
| Celldex Therapeutics | N/A | -52.35% | -47.61% |
Insider and Institutional Ownership
99.7% of Beam Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings and price targets for Beam Therapeutics and Celldex Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beam Therapeutics | 1 | 2 | 8 | 1 | 2.75 |
| Celldex Therapeutics | 1 | 1 | 11 | 0 | 2.77 |
Beam Therapeutics presently has a consensus price target of $46.40, suggesting a potential upside of 60.98%. Celldex Therapeutics has a consensus price target of $63.08, suggesting a potential upside of 112.90%. Given Celldex Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Celldex Therapeutics is more favorable than Beam Therapeutics.
Summary
Beam Therapeutics beats Celldex Therapeutics on 8 of the 15 factors compared between the two stocks.
About Beam Therapeutics
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
About Celldex Therapeutics
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
